PMID- 21652685 OWN - NLM STAT- In-Data-Review DA - 20110805 IS - 1528-0020 (Electronic) IS - 0006-4971 (Linking) VI - 118 IP - 5 DP - 2011 Aug 4 TI - Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). PG - 1413-20 AB - HSCT is being increasingly offered as a curative option for children with hematologic malignancies. Although survival has improved, the long-term morbidity ascribed to the HSCT procedure is not known. We compared the risk of chronic health conditions and adverse health among children with cancer treated with HSCT with survivors treated conventionally, as well as with sibling controls. HSCT survivors were drawn from BMTSS (N = 145), whereas conventionally treated survivors (N = 7207) and siblings (N = 4020) were drawn from CCSS. Self-reported chronic conditions were graded with CTCAEv3.0. Fifty-nine percent of HSCT survivors reported >/= 2 conditions, and 25.5% reported severe/life-threatening conditions. HSCT survivors were more likely than sibling controls to have severe/life-threatening (relative risk [RR] = 8.1, P < .01) and 2 or more (RR = 5.7, P < .01) conditions, as well as functional impairment (RR = 7.7, P < .01) and activity limitation (RR = 6.3, P < .01). More importantly, compared with CCSS survivors, BMTSS survivors demonstrated significantly elevated risks (severe/life-threatening conditions: RR = 3.9, P < .01; multiple conditions: RR = 2.6, P < .01; functional impairment: RR = 3.5, P < .01; activity limitation: RR = 5.8, P < .01). Unrelated donor HSCT recipients were at greatest risk. Childhood HSCT survivors carry a significantly greater burden of morbidity not only compared with noncancer populations but also compared with conventionally treated cancer patients, providing evidence for close monitoring of this high-risk population. AD - Population Sciences, City of Hope, Duarte, CA; FAU - Armenian, Saro H AU - Armenian SH FAU - Sun, Can-Lan AU - Sun CL FAU - Kawashima, Toana AU - Kawashima T FAU - Arora, Mukta AU - Arora M FAU - Leisenring, Wendy AU - Leisenring W FAU - Sklar, Charles A AU - Sklar CA FAU - Baker, K Scott AU - Baker KS FAU - Francisco, Liton AU - Francisco L FAU - Teh, Jennifer Berano AU - Teh JB FAU - Mills, George AU - Mills G FAU - Wong, F Lennie AU - Wong FL FAU - Rosenthal, Joseph AU - Rosenthal J FAU - Diller, Lisa R AU - Diller LR FAU - Hudson, Melissa M AU - Hudson MM FAU - Oeffinger, Kevin C AU - Oeffinger KC FAU - Forman, Stephen J AU - Forman SJ FAU - Robison, Leslie L AU - Robison LL FAU - Bhatia, Smita AU - Bhatia S LA - eng PT - Journal Article DEP - 20110607 PL - United States TA - Blood JT - Blood JID - 7603509 SB - AIM SB - IM EDAT- 2011/06/10 06:00 MHDA- 2011/06/10 06:00 CRDT- 2011/06/10 06:00 PHST- 2011/06/07 [aheadofprint] AID - blood-2011-01-331835 [pii] AID - 10.1182/blood-2011-01-331835 [doi] PST - ppublish SO - Blood. 2011 Aug 4;118(5):1413-20. Epub 2011 Jun 7. PMID- 21328523 OWN - NLM STAT- MEDLINE DA - 20110510 DCOM- 20110718 IS - 1545-5017 (Electronic) IS - 1545-5009 (Linking) VI - 57 IP - 1 DP - 2011 Jul 15 TI - Auditory complications in childhood cancer survivors: a report from the childhood cancer survivor study. PG - 126-34 LID - 10.1002/pbc.23025 [doi] AB - BACKGROUND: Studies have found associations between cancer therapies and auditory complications, but data are limited on long-term outcomes and risks associated with multiple exposures. PROCEDURE: The Childhood Cancer Survivor Study is a retrospective cohort investigating health outcomes of long-term survivors (5+ years) diagnosed and treated between 1970 and 1986 compared to a randomly selected sibling cohort. Questionnaires were completed by 14,358 survivors of childhood cancer and 4,023 sibling controls. Analysis determined the first occurrence of four auditory conditions in two time periods: diagnosis to 5 years post-diagnosis, and >/= 5 years post-diagnosis. Multivariable analyses determined the relative risks (RR) and 95% confidence interval (CI) of auditory conditions by treatment exposure. RESULTS: Five or more years from cancer diagnosis, survivors were at increased risk of problems hearing sounds (RR = 2.3; 95% CI: 1.8-2.8), tinnitus (RR = 1.7; 95% CI: 1.4-2.1), hearing loss requiring an aid (RR = 4.4; 95% CI: 2.8-6.9), and hearing loss in 1 or both ears not corrected by a hearing aid (RR = 5.2; 95% CI: 2.8-9.5), when compared to siblings. Temporal lobe and posterior fossa radiation was associated with these outcomes in a dose-dependent fashion. Exposure to platinum compounds was associated with an increased risk of problems hearing sounds (RR = 2.1; 95% CI: 1.3-3.2), tinnitus (RR = 2.8; 95% CI: 1.9-4.2), and hearing loss requiring an aid (RR = 4.1; 95% CI: 2.5-6.7). CONCLUSIONS: Childhood cancer survivors are at risk of developing auditory complications. Radiation and platinum compounds are determinants of this risk. Follow-up is needed to evaluate the impact of auditory conditions on quality of life. CI - Copyright (c) 2011 Wiley-Liss, Inc. AD - Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA. kwhelan@peds.uab.edu FAU - Whelan, Kimberly AU - Whelan K FAU - Stratton, Kayla AU - Stratton K FAU - Kawashima, Toana AU - Kawashima T FAU - Leisenring, Wendy AU - Leisenring W FAU - Hayashi, Susan AU - Hayashi S FAU - Waterbor, John AU - Waterbor J FAU - Blatt, Julie AU - Blatt J FAU - Sklar, Charles A AU - Sklar CA FAU - Packer, Roger AU - Packer R FAU - Mitby, Pauline AU - Mitby P FAU - Robison, Leslie L AU - Robison LL FAU - Mertens, Ann C AU - Mertens AC LA - eng GR - U24 CA55727/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20110215 PL - United States TA - Pediatr Blood Cancer JT - Pediatric blood & cancer JID - 101186624 RN - 0 (Platinum Compounds) SB - IM MH - Adolescent MH - Adult MH - Child MH - Child, Preschool MH - Female MH - Hearing Loss/*epidemiology/etiology MH - Humans MH - Infant MH - Infant, Newborn MH - Male MH - Middle Aged MH - Neoplasms/mortality/*therapy MH - Platinum Compounds/adverse effects/therapeutic use MH - *Quality of Life MH - Radiotherapy/adverse effects MH - Retrospective Studies MH - Risk Factors MH - Siblings MH - Time Factors MH - Young Adult PMC - PMC3091978 MID - NIHMS259040 OID - NLM: NIHMS259040 [Available on 07/15/12] OID - NLM: PMC3091978 [Available on 07/15/12] EDAT- 2011/02/18 06:00 MHDA- 2011/07/19 06:00 CRDT- 2011/02/18 06:00 PMCR- 2012/07/15 PHST- 2010/06/21 [received] PHST- 2010/12/14 [accepted] PHST- 2011/02/15 [aheadofprint] AID - 10.1002/pbc.23025 [doi] PST - ppublish SO - Pediatr Blood Cancer. 2011 Jul 15;57(1):126-34. doi: 10.1002/pbc.23025. Epub 2011 Feb 15. PMID- 21278355 OWN - NLM STAT- MEDLINE DA - 20110429 DCOM- 20110630 IS - 1528-0020 (Electronic) IS - 0006-4971 (Linking) VI - 117 IP - 17 DP - 2011 Apr 28 TI - Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. PG - 4442-8 AB - We evaluate the prevalence and risk factors of the metabolic syndrome (MS) in young adults surviving childhood leukemia. During the years 2007 to 2008, assessment of MS was proposed to all adults included in the Leucemie de l'Enfant et de l'Adolescent program, a French prospective multicentric cohort of leukemia survivors. Among 220 eligible patients, 184 (83.6%) had complete evaluation. Median age at evaluation and follow-up duration were 21.2 and 15.4 years. Overall prevalence of MS was 9.2% (95% confidence interval, 5.5-14.4). There was no association of MS with sex, age at diagnosis, leukemia subtype, steroid therapy, and central nervous system irradiation. Patients were stratified according to 4 therapeutic modalities: chemotherapy alone (n = 97), chemotherapy and central nervous system irradiation (n = 27), hematopoietic stem cell transplantation (HSCT) without (n = 17) or with (n = 43) total body irradiation (TBI). MS occurred in 5.2%, 11.1%, 5.9%, and 18.6% of them, respectively. The higher risk observed in the HSCT-TBI group was significant in univariate and in multivariate analysis (odds ratio [OR] = 3.9, P = .03). HSCT with TBI was associated with a higher rate of hypertriglyceridemia (OR = 4.5, P = .004), low level of high-density lipoprotein cholesterol (OR = 2.5, P = .02), and elevated fasting glucose (OR = 6.1, P = .04) So, TBI is a major risk factor for MS. Further studies are warranted to explain this feature. AD - Department of Pediatric Hematology, Hopital de la Timone Enfants, Marseille, France. oudinc@marseille.fnclcc.fr FAU - Oudin, Claire AU - Oudin C FAU - Simeoni, Marie-Claude AU - Simeoni MC FAU - Sirvent, Nicolas AU - Sirvent N FAU - Contet, Audrey AU - Contet A FAU - Begu-Le Coroller, Audrey AU - Begu-Le Coroller A FAU - Bordigoni, Pierre AU - Bordigoni P FAU - Curtillet, Catherine AU - Curtillet C FAU - Poiree, Maryline AU - Poiree M FAU - Thuret, Isabelle AU - Thuret I FAU - Play, Barbara AU - Play B FAU - Massot, Mara Carazza AU - Massot MC FAU - Chastagner, Pascal AU - Chastagner P FAU - Chambost, Herve AU - Chambost H FAU - Auquier, Pascal AU - Auquier P FAU - Michel, Gerard AU - Michel G LA - eng PT - Journal Article DEP - 20110128 PL - United States TA - Blood JT - Blood JID - 7603509 RN - 0 (Antineoplastic Agents) RN - 0 (Blood Glucose) RN - 0 (Cholesterol, HDL) RN - 0 (Steroids) SB - AIM SB - IM CIN - Blood. 2011 Apr 28;117(17):4404-5. PMID: 21527537 MH - Adolescent MH - Adult MH - Antineoplastic Agents/therapeutic use MH - Blood Glucose/metabolism MH - Child MH - Cholesterol, HDL/blood MH - Combined Modality Therapy MH - Female MH - Follow-Up Studies MH - Hematopoietic Stem Cell Transplantation MH - Humans MH - Hypertriglyceridemia/epidemiology MH - Male MH - Metabolic Syndrome X/*epidemiology/metabolism MH - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/*epidemiology MH - Prevalence MH - Prospective Studies MH - Risk Factors MH - Steroids/therapeutic use MH - Young Adult EDAT- 2011/02/01 06:00 MHDA- 2011/07/01 06:00 CRDT- 2011/02/01 06:00 PHST- 2011/01/28 [aheadofprint] AID - blood-2010-09-304899 [pii] AID - 10.1182/blood-2010-09-304899 [doi] PST - ppublish SO - Blood. 2011 Apr 28;117(17):4442-8. Epub 2011 Jan 28. PMID- 21128798 OWN - NLM STAT- MEDLINE DA - 20101206 DCOM- 20110111 LR - 20110421 IS - 1938-5404 (Electronic) IS - 0033-7587 (Linking) VI - 174 IP - 6 DP - 2010 Dec TI - Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. PG - 741-52 AB - Previous studies have indicated that thyroid cancer risk after a first childhood malignancy is curvilinear with radiation dose, increasing at low to moderate doses and decreasing at high doses. Understanding factors that modify the radiation dose response over the entire therapeutic dose range is challenging and requires large numbers of subjects. We quantified the long-term risk of thyroid cancer associated with radiation treatment among 12,547 5-year survivors of a childhood cancer (leukemia, Hodgkin lymphoma and non-Hodgkin lymphoma, central nervous system cancer, soft tissue sarcoma, kidney cancer, bone cancer, neuroblastoma) diagnosed between 1970 and 1986 in the Childhood Cancer Survivor Study using the most current cohort follow-up to 2005. There were 119 subsequent pathologically confirmed thyroid cancer cases, and individual radiation doses to the thyroid gland were estimated for the entire cohort. This cohort study builds on the previous case-control study in this population (69 thyroid cancer cases with follow-up to 2000) by allowing the evaluation of both relative and absolute risks. Poisson regression analyses were used to calculate standardized incidence ratios (SIR), excess relative risks (ERR) and excess absolute risks (EAR) of thyroid cancer associated with radiation dose. Other factors such as sex, type of first cancer, attained age, age at exposure to radiation, time since exposure to radiation, and chemotherapy (yes/no) were assessed for their effect on the linear and exponential quadratic terms describing the dose-response relationship. Similar to the previous analysis, thyroid cancer risk increased linearly with radiation dose up to approximately 20 Gy, where the relative risk peaked at 14.6-fold (95% CI, 6.8-31.5). At thyroid radiation doses >20 Gy, a downturn in the dose-response relationship was observed. The ERR model that best fit the data was linear-exponential quadratic. We found that age at exposure modified the ERR linear dose term (higher radiation risk with younger age) (P < 0.001) and that sex (higher radiation risk among females) (P = 0.008) and time since exposure (higher radiation risk with longer time) (P < 0.001) modified the EAR linear dose term. None of these factors modified the exponential quadratic (high dose) term. Sex, age at exposure and time since exposure were found to be significant modifiers of the radiation-related risk of thyroid cancer and as such are important factors to account for in clinical follow-up and thyroid cancer risk estimation among childhood cancer survivors. AD - Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, UA. pbhatti@fhcrc.org FAU - Bhatti, Parveen AU - Bhatti P FAU - Veiga, Lene H S AU - Veiga LH FAU - Ronckers, Cecile M AU - Ronckers CM FAU - Sigurdson, Alice J AU - Sigurdson AJ FAU - Stovall, Marilyn AU - Stovall M FAU - Smith, Susan A AU - Smith SA FAU - Weathers, Rita AU - Weathers R FAU - Leisenring, Wendy AU - Leisenring W FAU - Mertens, Ann C AU - Mertens AC FAU - Hammond, Sue AU - Hammond S FAU - Friedman, Debra L AU - Friedman DL FAU - Neglia, Joseph P AU - Neglia JP FAU - Meadows, Anna T AU - Meadows AT FAU - Donaldson, Sarah S AU - Donaldson SS FAU - Sklar, Charles A AU - Sklar CA FAU - Robison, Leslie L AU - Robison LL FAU - Inskip, Peter D AU - Inskip PD LA - eng GR - U24 CA55727/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, N.I.H., Intramural PT - Research Support, Non-U.S. Gov't DEP - 20101006 PL - United States TA - Radiat Res JT - Radiation research JID - 0401245 SB - IM SB - S MH - Age Factors MH - Child MH - Cohort Studies MH - Dose-Response Relationship, Radiation MH - Female MH - Humans MH - Male MH - Neoplasms/*radiotherapy MH - Neoplasms, Radiation-Induced/*etiology MH - Neoplasms, Second Primary/*etiology MH - Risk MH - Survivors MH - Thyroid Neoplasms/*etiology PMC - PMC3080023 MID - NIHMS269726 OID - NLM: NIHMS269726 [Available on 12/01/11] OID - NLM: PMC3080023 [Available on 12/01/11] EDAT- 2010/12/07 06:00 MHDA- 2011/01/12 06:00 CRDT- 2010/12/07 06:00 PMCR- 2011/12/01 PHST- 2010/10/06 [aheadofprint] AID - 10.1667/RR2240.1 [pii] AID - 10.1667/RR2240.1 [doi] PST - ppublish SO - Radiat Res. 2010 Dec;174(6):741-52. Epub 2010 Oct 6. PMID- 20638187 OWN - NLM STAT- MEDLINE DA - 20110530 DCOM- 20110727 IS - 1879-355X (Electronic) IS - 0360-3016 (Linking) VI - 80 IP - 3 DP - 2011 Jul 1 TI - Dose-volume analysis of radiation nephropathy in children: preliminary report of the risk consortium. PG - 840-4 AB - PURPOSE: To characterize kidney function in children and adolescents who had undergone radiation treatment that included parts of the kidney. METHODS AND MATERIALS: Patients receiving radiotherapy during childhood or adolescence were prospectively registered in Germany's Registry for the Evaluation of Side Effects after Radiation in Childhood and Adolescence (RiSK). Detailed information was recorded regarding radiation doses at the organs at risk since 2001 all over Germany. Toxicity evaluation was performed according to standardized Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria. RESULTS: Up to May 2009, 1086 patients from 62 centers were recruited, including 126 patients (median age, 10.2 years) who underwent radiotherapy to parts of the kidneys. Maximal late toxicity (median follow-up 28.5 months in 74 patients) was characterized as Grade 0 (n = 65), 1 (n = 7) or 2 (n = 2). All patients with late effects had received potentially nephrotoxic chemotherapy. A statistically significant difference between patients with and without Grade 1 toxicity, revealing higher exposed kidney volumes in patients with toxicity, was seen for the kidney volume exposed to 20 Gy (V20; p = 0.031) and 30 Gy (V30; p = 0.003). CONCLUSIONS: Preliminary data indicate that radiation-induced kidney function impairment is rare in current pediatric multimodal treatment approaches. In the future, RiSK will be able to provide further detailed data regarding dose-volume effect relationships of radiation-associated side effects in pediatric oncology patients. CI - Copyright (c) 2011 Elsevier Inc. All rights reserved. AD - Department of Radiotherapy, University Hospital of Munster, Germany. Tobias.Boelling@uni-muenster.de FAU - Bolling, Tobias AU - Bolling T FAU - Ernst, Iris AU - Ernst I FAU - Pape, Hildegard AU - Pape H FAU - Martini, Carmen AU - Martini C FAU - Rube, Christian AU - Rube C FAU - Timmermann, Beate AU - Timmermann B FAU - Fischedick, Karin AU - Fischedick K FAU - Kortmann, Rolf-Dieter AU - Kortmann RD FAU - Willich, Normann AU - Willich N LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20100716 PL - United States TA - Int J Radiat Oncol Biol Phys JT - International journal of radiation oncology, biology, physics JID - 7603616 SB - IM MH - Adolescent MH - Adult MH - Child MH - Child, Preschool MH - Germany MH - Humans MH - Infant MH - Kidney/drug effects/*radiation effects MH - Kidney Diseases/*etiology/pathology MH - Neoplasms/radiotherapy MH - Organs at Risk/pathology/radiation effects MH - Prospective Studies MH - Radiation Injuries/*etiology/pathology MH - Radiotherapy Dosage MH - Registries MH - Young Adult EDAT- 2010/07/20 06:00 MHDA- 2011/07/28 06:00 CRDT- 2010/07/20 06:00 PHST- 2009/12/10 [received] PHST- 2010/02/28 [revised] PHST- 2010/03/09 [accepted] PHST- 2010/07/16 [aheadofprint] AID - S0360-3016(10)00456-6 [pii] AID - 10.1016/j.ijrobp.2010.03.021 [doi] PST - ppublish SO - Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):840-4. Epub 2010 Jul 16. PMID- 19535773 OWN - NLM STAT- MEDLINE DA - 20090701 DCOM- 20090706 IS - 1460-2105 (Electronic) IS - 0027-8874 (Linking) VI - 101 IP - 13 DP - 2009 Jul 1 TI - Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. PG - 928-37 AB - BACKGROUND: Information on clinically verified stroke and transient ischemic attack (TIA) following Hodgkin lymphoma is scarce. We quantified the long-term risk of cerebrovascular disease associated with the use of radiotherapy and chemotherapy in survivors of Hodgkin lymphoma and explored potential pathogenic mechanisms. METHODS: We performed a retrospective cohort study among 2201 five-year survivors of Hodgkin lymphoma treated before age 51 between 1965 and 1995. We compared incidence rates of clinically verified stroke and TIA with those in the general population. We used multivariable Cox regression techniques to study treatment-related factors and other risk factors. All statistical tests were two-sided. RESULTS: After a median follow-up of 17.5 years, 96 patients developed cerebrovascular disease (55 strokes, 31 TIAs, and 10 with both TIA and stroke; median age = 52 years). Most ischemic events were from large-artery atherosclerosis (36%) or cardioembolisms (24%). The standardized incidence ratio for stroke was 2.2 (95% confidence interval [CI] = 1.7 to 2.8), and for TIA, it was 3.1 (95% CI = 2.2 to 4.2). The risks remained elevated, compared with those in the general population, after prolonged follow-up. The cumulative incidence of ischemic stroke or TIA 30 years after Hodgkin lymphoma treatment was 7% (95% CI = 5% to 8%). Radiation to the neck and mediastinum was an independent risk factor for ischemic cerebrovascular disease (hazard ratio = 2.5, 95% CI = 1.1 to 5.6 vs without radiotherapy). Treatment with chemotherapy was not associated with an increased risk. Hypertension, diabetes mellitus, and hypercholesterolemia were associated with the occurrence of ischemic cerebrovascular disease, whereas smoking and overweight were not. CONCLUSIONS: Patients treated for Hodgkin lymphoma experience a substantially increased risk of stroke and TIA, associated with radiation to the neck and mediastinum. Physicians should consider appropriate risk-reducing strategies. AD - Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - De Bruin, Marie L AU - De Bruin ML FAU - Dorresteijn, Lucille D A AU - Dorresteijn LD FAU - van't Veer, Mars B AU - van't Veer MB FAU - Krol, Augustinus D G AU - Krol AD FAU - van der Pal, Helena J AU - van der Pal HJ FAU - Kappelle, Arnoud C AU - Kappelle AC FAU - Boogerd, Willem AU - Boogerd W FAU - Aleman, Berthe M P AU - Aleman BM FAU - van Leeuwen, Flora E AU - van Leeuwen FE LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090617 PL - United States TA - J Natl Cancer Inst JT - Journal of the National Cancer Institute JID - 7503089 RN - 0 (Antineoplastic Agents, Hormonal) SB - IM CIN - J Natl Cancer Inst. 2009 Jul 1;101(13):904-5. PMID: 19535779 MH - Adult MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents, Hormonal/adverse effects MH - Cohort Studies MH - Female MH - Hodgkin Disease/drug therapy/*radiotherapy MH - Humans MH - Incidence MH - Ischemic Attack, Transient/*epidemiology/*etiology MH - Male MH - Mediastinum/radiation effects MH - Menopause, Premature MH - Middle Aged MH - Neck/radiation effects MH - Netherlands/epidemiology MH - Odds Ratio MH - Proportional Hazards Models MH - Radiation Injuries/*complications/*etiology MH - Radiotherapy/adverse effects MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Sex Factors MH - Stroke/*epidemiology/*etiology EDAT- 2009/06/19 09:00 MHDA- 2009/07/07 09:00 CRDT- 2009/06/19 09:00 PHST- 2009/06/17 [aheadofprint] AID - djp147 [pii] AID - 10.1093/jnci/djp147 [doi] PST - ppublish SO - J Natl Cancer Inst. 2009 Jul 1;101(13):928-37. Epub 2009 Jun 17. PMID- 17047152 OWN - NLM STAT- MEDLINE DA - 20070207 DCOM- 20070320 LR - 20091118 IS - 0006-4971 (Print) IS - 0006-4971 (Linking) VI - 109 IP - 4 DP - 2007 Feb 15 TI - Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. PG - 1765-72 AB - We ascertained the prevalence of self-reported late occurrence of diabetes, hypertension, and cardiovascular (CV) disease in 1089 hematopoietic cell transplantation (HCT) survivors who underwent HCT between 1974 and 1998, survived at least 2 years, and were not currently taking immunosuppressant agents and compared them with 383 sibling controls. All subjects completed a 255-item health questionnaire. The mean age at survey completion was 39.3 years for survivors and 38.6 years for siblings; mean follow-up was 8.6 years. Adjusting for age, sex, race, and body mass index (BMI), survivors of allogeneic HCT were 3.65 times (95% confidence interval [CI], 1.82-7.32) more likely to report diabetes than siblings and 2.06 times (95% CI, 1.39-3.04) more likely to report hypertension compared with siblings but did not report other CV outcomes with any greater frequency. Recipients of autologous HCTs were no more likely than siblings to report any of the outcomes studied. Allogeneic HCT survivors were also more likely to develop hypertension (odds ratio [OR]=2.31; 95% CI, 1.45-3.67) than autologous recipients. Total body irradiation (TBI) exposure was associated with an increased risk of diabetes (OR=3.42; 95% CI, 1.55-7.52). Thus, HCT survivors have a higher age- and BMI-adjusted risk of diabetes and hypertension, potentially leading to a higher than expected risk of CV events with age. AD - Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA. baker084@umn.edu FAU - Baker, K Scott AU - Baker KS FAU - Ness, Kirsten K AU - Ness KK FAU - Steinberger, Julia AU - Steinberger J FAU - Carter, Andrea AU - Carter A FAU - Francisco, Liton AU - Francisco L FAU - Burns, Linda J AU - Burns LJ FAU - Sklar, Charles AU - Sklar C FAU - Forman, Stephen AU - Forman S FAU - Weisdorf, Daniel AU - Weisdorf D FAU - Gurney, James G AU - Gurney JG FAU - Bhatia, Smita AU - Bhatia S LA - eng GR - K23 CA85503-01/CA/NCI NIH HHS/United States GR - R01 CA078938/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20061017 PL - United States TA - Blood JT - Blood JID - 7603509 SB - AIM SB - IM MH - Adult MH - Cardiovascular Diseases/epidemiology/*etiology MH - Case-Control Studies MH - Data Collection MH - Diabetes Mellitus/epidemiology/*etiology MH - Follow-Up Studies MH - Hematopoietic Stem Cell Transplantation/*adverse effects MH - Humans MH - Hypertension/epidemiology/*etiology MH - Prevalence MH - Siblings MH - Survivors MH - Transplantation, Autologous MH - Transplantation, Homologous MH - Whole-Body Irradiation/adverse effects PMC - PMC1794046 OID - NLM: PMC1794046 EDAT- 2006/10/19 09:00 MHDA- 2007/03/21 09:00 CRDT- 2006/10/19 09:00 PHST- 2006/10/17 [aheadofprint] AID - blood-2006-05-022335 [pii] AID - 10.1182/blood-2006-05-022335 [doi] PST - ppublish SO - Blood. 2007 Feb 15;109(4):1765-72. Epub 2006 Oct 17. PMID- 17007558 OWN - NLM STAT- MEDLINE DA - 20060929 DCOM- 20061120 LR - 20071203 IS - 0033-7587 (Print) IS - 0033-7587 (Linking) VI - 166 IP - 4 DP - 2006 Oct TI - Thyroid cancer in childhood cancer survivors: a detailed evaluation of radiation dose response and its modifiers. PG - 618-28 AB - Radiation exposure at a young age is a strong risk factor for thyroid cancer. We conducted a nested case-control study of 69 thyroid cancer cases and 265 controls from a cohort of 14,054 childhood cancer survivors to evaluate the shape of the radiation dose-response relationship, in particular at high doses, and to assess modification of the radiation effects by patient and treatment characteristics. We considered several types of statistical models to estimate the excess relative risk (ERR), mainly guided by radiobiological models. A two-parameter model with a term linear in dose and a negative exponential in dose squared provided the best parsimonious description with an ERR of 1.3 per gray (95% confidence interval 0.4-4.1) at doses below 6 Gy and a relative decrease in ERR of 0.2% per unit dose squared with increasing dose, that is, decreases in the ERR/Gy of 53% at 20 Gy and 95% at 40 Gy. Further analyses using spline models suggested that the significant nonlinearity at high doses was characterized most appropriately as a true downturn rather than a flattening of the dose-response curve. We found no statistically significant modification of the dose-response relationship by patient characteristics; however, the linear parameter (i.e., the ERR/ Gy at doses less than 6 Gy) did decrease consistently and linearly with increasing age at childhood cancer diagnosis, from 4.45 for 0-1-year-olds to 0.48 for 15-20-year-olds. In summary, we applied models derived from radiobiology to describe the radiation dose-response curve for thyroid cancer in an epidemiological study and found convincing evidence for a downturn in risk at high doses. AD - Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland. c.m.ronckers@amc.uva.nl FAU - Ronckers, Cecile M AU - Ronckers CM FAU - Sigurdson, Alice J AU - Sigurdson AJ FAU - Stovall, Marilyn AU - Stovall M FAU - Smith, Susan A AU - Smith SA FAU - Mertens, Ann C AU - Mertens AC FAU - Liu, Yan AU - Liu Y FAU - Hammond, Sue AU - Hammond S FAU - Land, Charles E AU - Land CE FAU - Neglia, Joseph P AU - Neglia JP FAU - Donaldson, Sarah S AU - Donaldson SS FAU - Meadows, Anna T AU - Meadows AT FAU - Sklar, Charles A AU - Sklar CA FAU - Robison, Leslie L AU - Robison LL FAU - Inskip, Peter D AU - Inskip PD LA - eng GR - CA 55727/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, N.I.H., Intramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Radiat Res JT - Radiation research JID - 0401245 SB - IM SB - S MH - Child MH - Disease-Free Survival MH - Dose-Response Relationship, Radiation MH - Female MH - Humans MH - Incidence MH - Male MH - Neoplasms/epidemiology/radiotherapy MH - *Proportional Hazards Models MH - Radiotherapy/*statistics & numerical data MH - Radiotherapy Dosage MH - Risk Assessment/*methods MH - Risk Factors MH - Survivors/*statistics & numerical data MH - Thyroid Neoplasms/*epidemiology MH - United States/epidemiology EDAT- 2006/09/30 09:00 MHDA- 2006/12/09 09:00 CRDT- 2006/09/30 09:00 PHST- 2005/11/15 [received] PHST- 2006/04/06 [accepted] AID - RR3605 [pii] AID - 10.1667/RR3605.1 [doi] PST - ppublish SO - Radiat Res. 2006 Oct;166(4):618-28. PMID- 16435004 OWN - NLM STAT- MEDLINE DA - 20060125 DCOM- 20060508 LR - 20071114 IS - 0268-3369 (Print) IS - 0268-3369 (Linking) VI - 37 IP - 3 DP - 2006 Feb TI - Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). PG - 249-61 AB - More than 40,000 hematopoietic cell transplants (HCTs) are performed worldwide each year. With improvements in transplant technology, larger numbers of transplant recipients survive free of the disease for which they were transplanted. However, there are late complications that can cause substantial morbidity. Many survivors are no longer under the care of transplant centers and many community health-care providers may be unfamiliar with health matters relevant to HCT. The Center for International Blood and Marrow Transplant Research (CIBMTR), European Group for Blood and Marrow Transplantation (EBMT), and American Society for Blood and Marrow Transplantation (ASBMT) have developed these recommendations to offer care providers suggested screening and prevention practices for autologous and allogeneic HCT survivors. AD - Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA. FAU - Rizzo, J D AU - Rizzo JD FAU - Wingard, J R AU - Wingard JR FAU - Tichelli, A AU - Tichelli A FAU - Lee, S J AU - Lee SJ FAU - Van Lint, M T AU - Van Lint MT FAU - Burns, L J AU - Burns LJ FAU - Davies, S M AU - Davies SM FAU - Ferrara, J L M AU - Ferrara JL FAU - Socie, G AU - Socie G LA - eng GR - K23-CA-82350/CA/NCI NIH HHS/United States GR - U24-CA76518/CA/NCI NIH HHS/United States PT - Guideline PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - England TA - Bone Marrow Transplant JT - Bone marrow transplantation JID - 8702459 SB - IM CIN - Bone Marrow Transplant. 2006 Apr;37(8):805-6. PMID: 16518421 MH - Delivery of Health Care/standards MH - Disease-Free Survival MH - Europe MH - Female MH - Health Personnel/standards MH - Hematopoietic Stem Cell Transplantation/methods/mortality/*standards MH - Humans MH - Male MH - Societies, Medical MH - United States EDAT- 2006/01/26 09:00 MHDA- 2006/05/09 09:00 CRDT- 2006/01/26 09:00 AID - 1705243 [pii] AID - 10.1038/sj.bmt.1705243 [doi] PST - ppublish SO - Bone Marrow Transplant. 2006 Feb;37(3):249-61. PMID- 16204692 OWN - NLM STAT- MEDLINE DA - 20051005 DCOM- 20051014 LR - 20061115 IS - 1460-2105 (Electronic) IS - 0027-8874 (Linking) VI - 97 IP - 19 DP - 2005 Oct 5 TI - Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. PG - 1428-37 AB - BACKGROUND: Many women develop breast cancer after treatment for Hodgkin lymphoma (HL) at a young age. We estimated this future risk, taking into account age and calendar year of HL diagnosis, HL treatment information, population breast cancer incidence rates, and competing causes of death. METHODS: Relative risks of breast cancer for categories defined by radiation dose to the chest (0, 20- < 40 Gy, or > or = 40 Gy) and use of alkylating agents (yes or no) were estimated from a case-control study conducted within an international population-based cohort of 3817 female 1-year survivors of HL diagnosed at age 30 years or younger from January 1, 1965, through December 31, 1994. To compute cumulative absolute risks of breast cancer, we used modified standardized incidence ratios to relate cohort breast cancer risks to those in the general population, enabling application of population-based breast cancer rates, and we allowed for competing risks by using population-based mortality rates in female HL survivors. RESULTS: Cumulative absolute risks of breast cancer increased with age at end of follow-up, time since HL diagnosis, and radiation dose. For an HL survivor who was treated at age 25 years with a chest radiation dose of at least 40 Gy without alkylating agents, estimated cumulative absolute risks of breast cancer by age 35, 45, and 55 years were 1.4% (95% confidence interval [CI] = 0.9% to 2.1%), 11.1% (95% CI = 7.4% to 16.3%), and 29.0% (95% CI = 20.2% to 40.1%), respectively. Cumulative absolute risks were lower in women treated with alkylating agents. CONCLUSIONS: Breast cancer projections varied considerably by type of HL therapy, time since HL diagnosis, and age at end of follow-up. These estimates are applicable to HL survivors treated with regimens of the past and can be used to counsel such patients and plan management and preventive strategies. Projections should be used with caution, however, in patients treated with more recent approaches, including limited-field radiotherapy and/or ovary-sparing chemotherapy. AD - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA. travisl@mail.nih.gov FAU - Travis, Lois B AU - Travis LB FAU - Hill, Deirdre AU - Hill D FAU - Dores, Graca M AU - Dores GM FAU - Gospodarowicz, Mary AU - Gospodarowicz M FAU - van Leeuwen, Flora E AU - van Leeuwen FE FAU - Holowaty, Eric AU - Holowaty E FAU - Glimelius, Bengt AU - Glimelius B FAU - Andersson, Michael AU - Andersson M FAU - Pukkala, Eero AU - Pukkala E FAU - Lynch, Charles F AU - Lynch CF FAU - Pee, David AU - Pee D FAU - Smith, Susan A AU - Smith SA FAU - Van't Veer, Mars B AU - Van't Veer MB FAU - Joensuu, Timo AU - Joensuu T FAU - Storm, Hans AU - Storm H FAU - Stovall, Marilyn AU - Stovall M FAU - Boice, John D Jr AU - Boice JD Jr FAU - Gilbert, Ethel AU - Gilbert E FAU - Gail, Mitchell H AU - Gail MH LA - eng PT - Journal Article PT - Research Support, N.I.H., Intramural PL - United States TA - J Natl Cancer Inst JT - Journal of the National Cancer Institute JID - 7503089 RN - 0 (Antineoplastic Agents, Alkylating) SB - IM CIN - J Natl Cancer Inst. 2005 Oct 5;97(19):1394-5. PMID: 16204683 MH - Adult MH - Antineoplastic Agents, Alkylating/administration & dosage/*adverse effects MH - Breast Neoplasms/*epidemiology/etiology MH - Case-Control Studies MH - Chemotherapy, Adjuvant/adverse effects MH - Cohort Studies MH - Denmark/epidemiology MH - Female MH - Finland/epidemiology MH - Hodgkin Disease/*drug therapy/*radiotherapy MH - Humans MH - Incidence MH - Iowa/epidemiology MH - Middle Aged MH - Neoplasms, Radiation-Induced/*epidemiology/etiology MH - Neoplasms, Second Primary/*epidemiology/etiology MH - Netherlands/epidemiology MH - Odds Ratio MH - Ontario/epidemiology MH - Radiotherapy Dosage MH - Radiotherapy, Adjuvant/adverse effects MH - Risk Assessment MH - Risk Factors MH - SEER Program MH - Sweden/epidemiology EDAT- 2005/10/06 09:00 MHDA- 2005/10/15 09:00 CRDT- 2005/10/06 09:00 AID - 97/19/1428 [pii] AID - 10.1093/jnci/dji290 [doi] PST - ppublish SO - J Natl Cancer Inst. 2005 Oct 5;97(19):1428-37. PMID- 12837833 OWN - NLM STAT- MEDLINE DA - 20030702 DCOM- 20030805 LR - 20071114 IS - 1460-2105 (Electronic) IS - 0027-8874 (Linking) VI - 95 IP - 13 DP - 2003 Jul 2 TI - Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. PG - 971-80 AB - BACKGROUND: Female survivors of Hodgkin's disease (HD) have a strongly elevated risk of breast cancer, but factors responsible for the increased risk are not well known. METHODS: We investigated the effects of radiation dose, chemotherapy (CT), and reproductive factors on breast cancer risk in a nested case-control study in The Netherlands in a cohort of 770 female patients who had been diagnosed with HD before age 41. Detailed treatment information and data on reproductive factors were collected for 48 case patients who developed breast cancer 5 or more years after diagnosis of HD and 175 matched control subjects. The radiation dose was estimated to the area of the breast where the case patient's tumor had developed and to a comparable location in matched control subjects. Relative risks (RRs) of breast cancer were calculated by conditional logistic regression. Statistical tests were two-sided. RESULTS: The risk of breast cancer increased statistically significantly with radiation dose (P(trend) =.01); patients who received 38.5 Gy or more had an RR of 4.5 (95% confidence interval [CI] = 1.3 to 16) times that of patients who received less than 4 Gy. Patients who received both CT and radiotherapy (RT) had a statistically significantly lower risk than those treated with RT alone (RR = 0.45, 95% CI = 0.22 to 0.91). Breast cancer risk increased with increasing radiation dose among patients who received RT only (RR = 12.7, 95% CI = 1.8 to 86, for patients receiving > or =38.5 Gy) but not among patients treated with CT and RT. Sixty-nine percent of control subjects treated with RT and more than six cycles of CT, but only 9% of those who received RT alone, reached menopause before age 41. Reaching menopause before age 36 was associated with a strongly reduced risk of breast cancer (RR = 0.06, 95% CI = 0.01 to 0.45). CONCLUSION: Breast cancer risk increases with increasing radiation dose up to at least 40 Gy. The substantial risk reduction associated with CT may reflect its effect on menopausal age, suggesting that ovarian hormones promote tumorigenesis after radiation has produced an initiating event. AD - Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. f.v.leeuwen@nki.nl FAU - van Leeuwen, Flora E AU - van Leeuwen FE FAU - Klokman, Willem J AU - Klokman WJ FAU - Stovall, Marilyn AU - Stovall M FAU - Dahler, Ellen C AU - Dahler EC FAU - van't Veer, Mars B AU - van't Veer MB FAU - Noordijk, Evert M AU - Noordijk EM FAU - Crommelin, Mariad A AU - Crommelin MA FAU - Aleman, Berthe M P AU - Aleman BM FAU - Broeks, Annegien AU - Broeks A FAU - Gospodarowicz, Mary AU - Gospodarowicz M FAU - Travis, Lois B AU - Travis LB FAU - Russell, Nicola S AU - Russell NS LA - eng GR - N01-CP-91024/CP/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Natl Cancer Inst JT - Journal of the National Cancer Institute JID - 7503089 RN - 0 (Hormones) SB - IM CIN - J Natl Cancer Inst. 2003 Oct 15;95(20):1552. PMID: 14559880 CIN - J Natl Cancer Inst. 2003 Jul 2;95(13):928-9. PMID: 12837820 MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse effects MH - Breast Neoplasms/*etiology/metabolism MH - Case-Control Studies MH - Chemotherapy, Adjuvant MH - Confidence Intervals MH - Dose-Response Relationship, Radiation MH - Female MH - Hodgkin Disease/*drug therapy/metabolism/*radiotherapy MH - Hormones/*metabolism MH - Humans MH - Middle Aged MH - Neoplasms, Second Primary/*etiology/metabolism MH - Odds Ratio MH - Radiotherapy Dosage MH - Radiotherapy, Adjuvant/adverse effects MH - Risk EDAT- 2003/07/03 05:00 MHDA- 2003/08/06 05:00 CRDT- 2003/07/03 05:00 PST - ppublish SO - J Natl Cancer Inst. 2003 Jul 2;95(13):971-80. PMID- 12485966 OWN - NLM STAT- MEDLINE DA - 20021217 DCOM- 20021220 LR - 20061115 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 106 IP - 25 DP - 2002 Dec 17 TI - Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. PG - 3143-421 CN - National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) LA - eng PT - Guideline PT - Journal Article PT - Practice Guideline PL - United States TA - Circulation JT - Circulation JID - 0147763 RN - 0 (Cholesterol, HDL) RN - 0 (Cholesterol, LDL) RN - 0 (Triglycerides) RN - 57-88-5 (Cholesterol) SB - AIM SB - IM CIN - Circulation. 2002 Dec 17;106(25):e9068-8. PMID: 12485977 CIN - Circulation. 2002 Dec 17;106(25):3140-1. PMID: 12485965 MH - Adult MH - Cholesterol/*blood MH - Cholesterol, HDL/blood MH - Cholesterol, LDL/blood MH - Coronary Disease/prevention & control MH - Diet MH - Diet Therapy MH - Disease Management MH - Drug Therapy MH - Female MH - *Health Education MH - Humans MH - Hypercholesterolemia/blood/*diagnosis/ethnology/*therapy MH - Hyperlipidemias/blood/diagnosis/therapy MH - Life Style MH - Male MH - Nutrition Surveys MH - Reference Values MH - Risk Assessment MH - Risk Reduction Behavior MH - Triglycerides/blood EDAT- 2002/12/18 04:00 MHDA- 2002/12/21 04:00 CRDT- 2002/12/18 04:00 PST - ppublish SO - Circulation. 2002 Dec 17;106(25):3143-421. PMID- 11878576 OWN - NLM STAT- MEDLINE DA - 20020306 DCOM- 20020321 LR - 20071115 IS - 1077-4114 (Print) IS - 1077-4114 (Linking) VI - 23 IP - 7 DP - 2001 Oct TI - Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia. PG - 424-30 AB - PURPOSE: To assess cardiovascular risk factors (CVRF) in young adult survivors of childhood acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: Twenty-six subjects (median age, 20.9 years; median interval since completion of therapy, 13.3 years) were evaluated. Ten participants had received cranial irradiation (CRT), whereas 16 had received only chemotherapy. Primary outcome measures included body mass index (BMI), blood pressure, fasting lipoprotein, glucose, and insulin levels. Secondary measures included insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 levels, physical activity index, a 7-day dietary recall, tobacco product use, and measurement of the intima-media thickness (IMT) of the common carotid artery. RESULTS: Sixty-two percent (16/26) of participants had at least one CVRF potentially related to their cancer treatment (obesity, dyslipidemia, increased blood pressure, or insulin resistance), with 30% (7/26) having more than two CVRF. Thirty-one percent (8/26) of subjects were obese (BMI > or = 30). Subjects who were treated with CRT (BMI, 30.4 +/- 6.7) had an increased BMI (P = 0.039) in comparison with those who received only chemotherapy (BMI, 25.4 +/- 5.1). Triglyceride and very low-density lipoprotein C levels were significantly higher in those treated with CRT (P = 0.027 and 0.022, respectively). The IGF-1 was inversely correlated with IMT (total group, -0.514, P = 0.009; females only, -0.729, P = 0.003). CONCLUSIONS: Young adult survivors of childhood ALL, especially those treated with CRT, are at risk for obesity and dyslipidemia, insulin resistance, hypertension, and cardiovascular disease. Further investigation of these risks is warranted. AD - Department of Family Practice and Community Medicine, The University of Texas Southwestern Medical Center at Dallas, 75390-9067, USA. kevin.oeffinger@email.swmed.edu FAU - Oeffinger, K C AU - Oeffinger KC FAU - Buchanan, G R AU - Buchanan GR FAU - Eshelman, D A AU - Eshelman DA FAU - Denke, M A AU - Denke MA FAU - Andrews, T C AU - Andrews TC FAU - Germak, J A AU - Germak JA FAU - Tomlinson, G E AU - Tomlinson GE FAU - Snell, L E AU - Snell LE FAU - Foster, B M AU - Foster BM LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Pediatr Hematol Oncol JT - Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology JID - 9505928 SB - IM MH - Adolescent MH - Adult MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Cardiovascular Diseases/*etiology MH - Carotid Artery, Common/pathology MH - Child MH - Child, Preschool MH - Combined Modality Therapy MH - Cranial Irradiation/adverse effects MH - Female MH - Humans MH - Hyperlipidemias/etiology MH - Hypertension/etiology MH - Infant MH - Male MH - Obesity/etiology MH - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy MH - Risk Factors MH - Survivors EDAT- 2002/03/07 10:00 MHDA- 2002/03/22 10:01 CRDT- 2002/03/07 10:00 PST - ppublish SO - J Pediatr Hematol Oncol. 2001 Oct;23(7):424-30. PMID- 10849486 OWN - NLM STAT- MEDLINE DA - 20000710 DCOM- 20000710 LR - 20041117 IS - 0105-6263 (Print) IS - 0105-6263 (Linking) VI - 23 Suppl 2 DP - 2000 TI - Semen banking in patients with cancer: 20-year experience. PG - 16-9 AB - Modern techniques of banking sperm provide an effective way to preserve the option of future fertility for most teenagers and young men diagnosed with a variety of malignancies that will necessitate treatment with chemotherapy, pelvic surgery, or significant radiation doses to the testes. Results of cumulative data collected at the Cleveland Clinic Foundation from patients with testicular cancer, lymphoma, leukemia, sarcoma, carcinoma and other kinds of malignancy have revealed that: (1) pretreatment semen quality (pre-freeze and post-thaw) in patients with cancer is poorer compared with healthy donors; (2) the percentage decline in semen quality (from pre-freeze to post-thaw) in patients with cancer is similar to that of normal donors. This suggested that the effect of cryodamage on spermatozoa from patients with cancer is similar to that of normal donors. (3) The stage of cancer in patients with testicular cancer and Hodgkin's disease shows no relationship to their semen quality. Based on studies conducted at the Cleveland Clinic Foundation, we recommend that sperm cryopreservation be offered to all men of reproductive age who have malignancies. Cryopreservation is safe and inexpensive, and gives patients a chance to establish pregnancies in the future with an assisted reproductive technique. AD - Center for Advanced Research in Human Reproduction and Infertility, Departments of Urology, Gynecology & Obstetrics, The Cleveland Clinic Foundation, Cleveland, OH, USA. FAU - Agarwal, A AU - Agarwal A LA - eng PT - Journal Article PL - ENGLAND TA - Int J Androl JT - International journal of andrology JID - 8000141 SB - IM MH - Feasibility Studies MH - Humans MH - Male MH - Neoplasms/*physiopathology MH - *Semen Preservation EDAT- 2000/06/13 09:00 MHDA- 2000/07/15 11:00 CRDT- 2000/06/13 09:00 AID - ija005 [pii] PST - ppublish SO - Int J Androl. 2000;23 Suppl 2:16-9. PMID- 4312366 OWN - NLM STAT- MEDLINE DA - 19700302 DCOM- 19700302 LR - 20051117 IS - 0031-4005 (Print) IS - 0031-4005 (Linking) VI - 44 IP - 6 DP - 1969 Dec TI - Long-term follow-up of renal functions of 108 children who underwent nephrectomy for malignant disease. PG - 912-21 FAU - Mitus, A AU - Mitus A FAU - Tefft, M AU - Tefft M FAU - Fellers, F X AU - Fellers FX LA - eng PT - Journal Article PL - UNITED STATES TA - Pediatrics JT - Pediatrics JID - 0376422 RN - 60-27-5 (Creatinine) SB - AIM SB - IM MH - Adenocarcinoma/surgery MH - Bacteriuria/epidemiology MH - Blood Urea Nitrogen MH - Child MH - Child, Preschool MH - Creatinine MH - Female MH - Follow-Up Studies MH - Humans MH - Infant MH - Kidney/physiopathology/*radiation effects MH - Kidney Function Tests MH - Kidney Neoplasms/drug therapy/radiotherapy/*surgery MH - Male MH - *Nephrectomy MH - Neuroblastoma/surgery MH - *Radiation Effects MH - Radionuclide Imaging MH - Time Factors MH - Urinary Tract Infections/etiology MH - Urine/analysis MH - Urography MH - Wilms Tumor/surgery EDAT- 1969/12/01 MHDA- 1969/12/01 00:01 CRDT- 1969/12/01 00:00 PST - ppublish SO - Pediatrics. 1969 Dec;44(6):912-21.